Mylan's generic Prilosec does not infringe on AZ patent

US generics giant Mylan's release of a generic version of the Anglo-Swedish major drug firm AstraZeneca's branded proton pump inhibitor Prilosec (omeprazole), does not infringe on the latter firm's patent, the US Court of Appeals for the Federal Circuit has found. The decision supports a May 2007 ruling from a District Court. Mylan launched omeprazole in 2003 after AstraZeneca's patent protection expired in 2002. Robert Court, Mylan's chief executive, commented that the firm believes "this decision ends the patent litigation surrounding this product for our company."